Last reviewed 2026-04-20 · How we verify

DOXYCYCLINE ANHYDROUS

FDA-approved approved Small molecule Quality 0/100

DOXYCYCLINE ANHYDROUS is a drug. It is currently FDA-approved (first approved 1967).

Doxycycline Anhydrous is a marketed antibiotic with a key composition patent expiring in 2028. Its long-standing market presence and broad spectrum of activity against various bacterial infections serve as key strengths. The primary risk is the potential increase in generic competition following the 2028 patent expiry.

At a glance

Generic name	DOXYCYCLINE ANHYDROUS
Modality	Small molecule
Phase	FDA-approved
First approval	1967

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Use of Oracea and Epiduo Forte in Severe Acne Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DOXYCYCLINE ANHYDROUS CI brief — competitive landscape report
DOXYCYCLINE ANHYDROUS updates RSS · CI watch RSS

Frequently asked questions about DOXYCYCLINE ANHYDROUS

What is DOXYCYCLINE ANHYDROUS?

DOXYCYCLINE ANHYDROUS is a Small molecule drug.

When was DOXYCYCLINE ANHYDROUS approved?

DOXYCYCLINE ANHYDROUS was first approved on 1967.

What development phase is DOXYCYCLINE ANHYDROUS in?

DOXYCYCLINE ANHYDROUS is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing